Skip to main content
SpringerLink
Log in

ALX 111

ALX1-11, PTH, Parathyroid hormone (1–84) — Allelix, Recombinant Human Parathyroid Hormone, rhPTH(1–84)

  • Adis R&D Profile
  • Section 1: Osteoporosis
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Groen EWJ, Schwietert HR, Van Marle SP, et al. Multiple dose administration of recombinant human parathyroid hormone in healthy postmenopausal volunteers [abstract]. Therapie 1995; 50 Suppl.: 525

    Google Scholar 

  2. Allelix Biopharmaceuticals. Allelix announces positive phase II results on ALX1–11 [media release]. Allelix Biopharmaceuticals, 1998 Oct 23

  3. Schwietert HR, Groen EWJ, Sollie FAE, et al. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1–84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther 1997 Mar; 61: 360–76

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

ALX 111. Drugs R&D 1, 211–212 (1999). https://doi.org/10.2165/00126839-199901030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901030-00003

Keywords

Search

Navigation